Science News from ESC 2017
August 26 – 30, 2017 | Barcelona, Spain
AHA's SCIENCE NEWS covers selected late-breaking clinical trials (Hot Line trials) presented daily at ESC Congress 2017 with exclusive video interviews plus data summaries, as well as links to related simultaneous publications and important AHA resources.
Sun., Aug. 27: Hot Line 1
Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results
John William Eikelboom | McMaster University, Hamilton, Ontario, Canada
- RESULTS: Rivaroxaban plus aspirin better for CV secondary prevention
- Summary of Eikelboom's data (PDF)
- Simultaneous publication in NEJM(link opens in new window) (opens in new window)
COMPASS PAD- Cardiovascular OutcoMes for People using Anticoagulation StrategieS trial: Results in Patients with Peripheral Artery Disease
Sonia Anand | McMaster University, Hamilton, Ontario, Canada
- RESULTS: Less adverse events for PAD patients with rivaroxaban plus aspirin than aspirin alone
- Summary of Anand's data (PDF)
CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Paul M. Ridker | Brigham and Women's Hospital, Boston, MA
- RESULTS: Canakinumab targets inflammatory pathway and provides CV and cancer risk benefit
- Summary of Ridker's data (PDF)
- Simultaneous publication in NEJM(link opens in new window) (opens in new window)
Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: the CASTLE-AF trial
Nassir Marrouch | University of Utah, Salt Lake City, UT
- RESULTS: Ablation helps in HF with AF
Also published today in Circulation:
- Efficacy and Safety of a Pharmaco-Invasive Strategy with Half-Dose Alteplase versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: The EARLY-MYO Trial
- Recalibrating Reperfusion Waypoints
- Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program 1995 to 2015
Mon., Aug 28: Hot Lines 2 & 3
An international multicenter clustered randomized trial to IMProve treatment with oral AntiCoagulanTs in Atrial Fibrillation
Christopher B. Granger | Duke University, Durham, NC
- RESULTS: Use of AF therapies better with customized education and support
- Summary of Granger's data (PDF)
- Simultaneous publication in The Lancet: A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial
Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial
Michael D. Ezekowitz | Lankenau Medical Center, Wynnewood, PA
- RESULTS: Stroke risk lowered by apixaban for AF and elective cardioversion
- Summary of Ezekowitz's data (PDF)
The PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
Frank Ruschitzka | Universität Zürich, Zurich, Switzerland
- RESULTS: Chronic ibuprofen use associated with BP increase in arthritis patient sub-study
- Summary of Ruschitzka's data (PDF)
- Article: Chronic NSAID use and Ambulatory Blood Pressure: PRECISION-ABPM in Perspective - with Elliot Antman, MD
A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease
Brian A Ference | DMC Harper University Hospital, Detroit, MI
- RESULTS: LDL: How you lower it matters
- Summary of Ference's data (PDF)
Airway management during cardiopulmonary resuscitation: Tracheal intubation versus bag valve mask ventilation
Frederic Adnet | Hôpital Avicenne, Bobigny, France
- RESULTS: Bag-mask ventilation not better than endotracheal intubation in OOH cardiac arrest; other issues noted
- Summary of Adnet's data (PDF)
Also published today in Circulation:
- Derivation and Validation of a Novel Right Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices: the EUROMACS-RHF Risk Score
- When VAD Things Happen to Good People
- The Prognostic Value of Coronary Artery Calcium in the PROMISE Study
- Computed Tomography or Functional Stress Testing for the Prediction of Risk: Can I have my cake and eat it?
Tue., Aug 29: Hot Line 4
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification (HPS3/TIMI55-REVEAL) trial
Martin Landray | University of Oxford, Oxford, UK
- RESULTS: CETP inhibitor reduced major coronary events
- Summary of Landray's data (PDF)
Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation (The REHEARSE-AF study)
Julian Halcox | Swansea University Medical School, Swansea, UK
- RESULTS: Hand-held device increased chances to find asymptomatic AF
- Summary of Halcox's data (PDF)
- Simultaneous publication in Circulation: Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study
- Editorial in Circulation: Atrial Fibrillation: Atrial High-Rate Events (AHRES): Look and You Will Find–Then What?
- Article: Smartphone device helps detect irregular heartbeat